

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

July 23, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled **"Biocon Biologics Launches Nepexto[®], a Biosimilar to Enbrel[®] (Etanercept), in Australia"**.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand**Company Secretary**

Membership No. ACS 13669

Address: Biocon House, Semicon Park

Tower 3, Electronic City Phase 2, Hosur Road

Bengaluru, Karnataka

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics Launches Nepexto[®], a Biosimilar to Enbrel[®] (Etanercept), in Australia

Bengaluru, Karnataka, India, July 23, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today it has launched Nepexto[®], a biosimilar to the reference product Enbrel[®] (Etanercept), in Australia. Nepexto[®] will be promoted by Generic Health, our local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia.

Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.

Since receiving EU marketing authorization in 2020, Nepexto[®] has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto[®] into new markets worldwide and further strengthen our immunology offering.

– Company Spokesperson

Nepexto[®] is a registered trademark of Biosimilars New Co Limited, a Biocon Biologics Company. All other trademarks are the property of their respective owners.